Swamy model lie exposed: Ministry says Priyanka, Karti have only one DIN

[email protected] (CD Network)
June 29, 2014

New Delhi, Jun 29: The credibility of senior BJP leader Subramanian Swamy, who is considered as one of the most controversial politicians in India, is once again at stake as his allegation against two prominent figures of opposition also proved to be false.

priyanka-karti-subbuPriyanka Gandhi and Karti Chidambaram have only one Director Identification Number (DIN) issued to them, Corporate Affairs Ministry has said contradicting the vociferous claim of senior Bharatiya Janata Party (BJP) leader Subramanian Swamy that they possessed multiple numbers.

The Ministry has also said that other DIN applications (online) made by them had "lapsed" or were "rejected" and not allotted to them. "Priyanka Gandhi, wife of Robert Vadra, is holding only one DIN allotted by Ministry. The DIN application was made online and processed by the DIN cell assisted by service provider company under MCA21.

"The valid DIN number... was allotted on her application dated January 10, 2007," Pankaj Srivastava, Assistant Central Public Information Officer, Office of Regional Director, NR, Noida said in an RTI response dated June 17, 2014 to Bhilwara- based RTI activist SS Ranawat.

"No penalty order was passed by this Directorate as the power to impose is vested with Courts under the provisions of the Companies Act, 1956," the reply said in response to a question seeking a copy of any penalty orders imposed on her.

The issue was raised by Subramanian Swamy who had filed complaints against Priyanka Vadra and Karti Chidambaram with the Ministry alleging that the two had multiple DINs, which is not permissible under the Companies Law.

Karti Chidambaram is the son of former Finance Minister P Chidambaram.

In the case of Karti also, the Ministry said in its response that he is "holding only one DIN allotted by the Ministry. The DIN application was made online and processed by the DIN cell assisted by service provider company under MCA21."

"However, the DIN documents and related information are in the nature of personal information and the disclosure of which has no relationship to any public activity or interest or which would cause unwarranted invasion of the privacy of the individuals as prescribed under section 8(1)(j) of the Right to Information Act," it said.

Comments

SS Ranawat
 - 
Sunday, 29 Jan 2017

This news is totally fake. In fact both the persons have DI number more than one. I have sufficient documentary evidences, which PTI ignored for the reasons best known to them.

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
February 17,2020

Mangaluru, Feb 17: Kambala superstar Shrinivas Gowda, who is drawing comparisons to ace sprinter Usain Bolt, has reportedly refused to take part in athletics trials with the Sports Authority of India.

28-year-old Gowda, who hails from Moodbidri in Dakshina Kannada, was celebrated as a potential Olympian after a clip of his race went viral, amid claims that he had done 100m in 9.55 seconds, against Bolt's record of 9.58. He has so far won 32 medals in 11 kambala events this season.

Union sports minister Kiren Rijiju and SAI said Gowda would appear for trials at SAI's Bengaluru centre on Monday. The government "will do everything to identify sporting talents", Rijiju had tweeted.

"I will meet the Chief Minister. I am keen on continuing in kambala," Gowda said. Asked about the clamour for a crossover into athletics, he said, "For the time being I have no plans to appear for SAI trials. I am busy with the Kambala season and will consider meeting them following that and after consulting my well-wishers."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 25,2020

Mangaluru, Apr 25: The Mangalore Refinery and Petrochemicals Limited (MRPL) has extended vital assistance to hundreds of migrant workers, destitute and needy families during the COVID-19 crisis through its CSR fund.

The lockdown has left thousands of people including migrant workers and destitute in the district, in the lurch. MRPL, using its corporate social responsibility fund through the Dakshina Kannada district administration, has sponsored 50,000 kg rice for the benefit of these needy citizens, a company release here said.

MRPL also donated grocery kits comprising boiled rice, dal, rava, sugar and tea to the needy families in the district, it said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
coastaldigest.com web desk
July 1,2020

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.